Western blot analysis of expression and phosphorylation of wild-type and mutated FGFR4 and its downstream target, STAT3, after treatment with 0, 200, and 800 nM concentrations of p... by Samuel Q. Li (466819)

“…(C-D) Western blot shows a dose-dependent decrease in STAT3 phosphorylation after treatment with ponatinib for three fusion-positive (RH4, RH5, and RH41) and one fusion-negative (CTR) RMS cell lines as well as the two RMS772 cell lines expressing the FGFR4 mutations N535K and V550E.…”

The funnel plot of visual analog scale score. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

Intervention characteristics of included studies. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

GRADE evaluation of evidence quality. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

PRISMA flow diagram. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

Summary data and analyses. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

The funnel plot of Harris hip score. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

Binarized cross recurrence plot of the MT-M1 functional connectivity. by Clara Rodriguez-Sabate (4512394)

“…The PD group shows a decrease of the ON-ON match density in both the resting-task block (Fig 5B) and the motor-task block (Fig 5D).…”

Highly Porous, Hydrophobic, and Compressible Cellulose Nanocrystals/Poly(vinyl alcohol) Aerogels as Recyclable Absorbents for Oil–Water Separation by Xiaoyu Gong (2284477)

“…With the three-dimensional interconnected microstructure, the aerogels were highly porous (porosity >97.7%) and ultralight with a density ranging from 22.5 to 36.1 mg/cm³ and floatable on the water surface. …”

Highly Porous, Hydrophobic, and Compressible Cellulose Nanocrystals/Poly(vinyl alcohol) Aerogels as Recyclable Absorbents for Oil–Water Separation by Xiaoyu Gong (2284477)

“…With the three-dimensional interconnected microstructure, the aerogels were highly porous (porosity >97.7%) and ultralight with a density ranging from 22.5 to 36.1 mg/cm³ and floatable on the water surface. …”

Single-instance population averaging predicts human spatial perception. by Helge Gleiss (7053491)

“…Conventions as in (A). (C) Average D(mean) across all cells (<i>n</i> = 13) decreased for the concurrent HPR, suggesting a relative worsening of the ability to distinguish adjacent ILDs by −15.5% (right-hand panel). …”

Quantitative comparison of protein expression between two <i>P</i>. <i>vivax</i> salivary gland sporozoite field isolates. by Kristian E. Swearingen (2301094)

“…Points in red are proteins with that were not significant at a 5.0% false discovery rate (FDR) according to the G-test. …”

Germination and biochemical changes in West Indian gherkin seeds under water stress at different temperatures by João Paulo Nobre de Almeida (4659739)

“…The experimental design was completely randomized, in 5 x 5 factorial scheme, composed of five osmotic potentials (0.0; -0.1; -0.2; -0.3 and -0.4 MPa) and four temperatures (20; 25; 30 °C and alternating temperatures of 20-30 ºC), with each treatment composed of four replicates of 50 seeds. …”

8oxoG inhibits TRF1 binding to telomeric DNA by Patricia L. Opresko (7493)

“…All rights reserved</p> Boxes indicate the GGG runs of the tandem telomeric repeats, and (X) marks the position of the 8oxoG lesion(s) within the G runs (see ). Substrates (2.5 nM) were incubated alone (−) or together with decreasing concentrations of purified TRF1 (200, 100, 50 or 25 nM) (lanes 2–5, 7–10, and 12–15, 17–20, 22–25 and 27–30) for 20 min at 4°C in TEL buffer. …”

The <i>I</i>_K1/Kir2.1 channel agonist zacopride prevents and cures acute ischemic arrhythmias in the rat by Xu-Wen Zhai (4033601)

“…However, clinical anti-arrhythmic agents that primarily act on RMP by enhancing the <i>I</i>_K1 channel are not currently available. We hypothesized that zacopride, a selective and moderate agonist of the <i>I</i>_K1/Kir2.1 channels, prevents and cures acute ischemic arrhythmias. …”

Image_1_Optimizing estradiol level for gonadotrophin-releasing hormone antagonist initiation among patients with simple tubal factor infertility.jpg by Yizhuo Wang (5132726)

“…Through smooth curve fitting, we found that, with the increase of serum E₂ levels on the day of GnRH-ant initiation, CPR showed a trend of slight increase and then slight decrease. …”

Sleep-related changes in breathing. by Stefano Bastianini (130236)

“…<p>(A) and (B), values of minute volume (V_E) and breath duration (T_TOT), respectively, during non-rapid-eye-movement sleep (N) and rapid-eye-movement sleep (R). …”

Effects of thermal stability on microcrustacean assemblages in spring fens by David Výravský (14052484)

PTE down-regulated the expression of SBP-1 and SCD. by YiHong Ding (689964)

“…(b) Relative expression levels of <i>sbp-1</i>, <i>fat-5</i>, <i>fat-6</i>, and <i>fat-7</i> measured by QPCR were significantly decreased with the increased concentrations of PTE. …”

Effects of task optimization on pareidolia representations in CNNs. by Pranjul Gupta (20623949)

“…Conversely, in CNNs lacking object categorization training (Panels B, C), this similarity was weak, only reaching significance at early layers, and decreased across layers. The Dual-task CNN showed a unique representational pattern where pareidolia faces were represented closer to matched objects than to real faces (‘Pareidolia  ~  Objects’; orange line), while still being more similar to real faces than objects (‘Pareidolia  ~  Faces’; blue line) from mid-layers (layer 5) onward, matching pareidolia representations in MEG (c.f. …”